WO2004035746A3 - Susceptibility gene for myocardial infarction - Google Patents

Susceptibility gene for myocardial infarction Download PDF

Info

Publication number
WO2004035746A3
WO2004035746A3 PCT/US2003/032805 US0332805W WO2004035746A3 WO 2004035746 A3 WO2004035746 A3 WO 2004035746A3 US 0332805 W US0332805 W US 0332805W WO 2004035746 A3 WO2004035746 A3 WO 2004035746A3
Authority
WO
WIPO (PCT)
Prior art keywords
myocardial infarction
susceptibility gene
locus
gene
susceptibility
Prior art date
Application number
PCT/US2003/032805
Other languages
French (fr)
Other versions
WO2004035746A2 (en
Inventor
Anna Helgadottir
Jeffrey R Gulcher
Andrei Manolescu
Original Assignee
Decode Genetics Ehf
Anna Helgadottir
Jeffrey R Gulcher
Andrei Manolescu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics Ehf, Anna Helgadottir, Jeffrey R Gulcher, Andrei Manolescu filed Critical Decode Genetics Ehf
Priority to AU2003290527A priority Critical patent/AU2003290527A1/en
Priority to CA002502359A priority patent/CA2502359A1/en
Priority to EP03783063A priority patent/EP1562973A4/en
Priority to US10/829,674 priority patent/US7507531B2/en
Publication of WO2004035746A2 publication Critical patent/WO2004035746A2/en
Priority to US10/587,412 priority patent/US20080293750A1/en
Publication of WO2004035746A3 publication Critical patent/WO2004035746A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Linkage of Myocardial Infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by association analysis to be a susceptibility gene for MI. Pathway targeting for drug delivery and diagnosis applications in identifying those have MI or at risk of developing MI, in particular are described.
PCT/US2003/032805 2002-10-17 2003-10-16 Susceptibility gene for myocardial infarction WO2004035746A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2003290527A AU2003290527A1 (en) 2002-10-17 2003-10-16 Susceptibility gene for myocardial infarction
CA002502359A CA2502359A1 (en) 2002-10-17 2003-10-16 Susceptibility gene for myocardial infarction
EP03783063A EP1562973A4 (en) 2002-10-17 2003-10-16 Susceptibility gene for myocardial infarction
US10/829,674 US7507531B2 (en) 2002-10-17 2004-04-22 Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US10/587,412 US20080293750A1 (en) 2002-10-17 2005-01-31 Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41943202P 2002-10-17 2002-10-17
US60/419,432 2002-10-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US76954204A Continuation-In-Part 2002-10-17 2004-01-30

Publications (2)

Publication Number Publication Date
WO2004035746A2 WO2004035746A2 (en) 2004-04-29
WO2004035746A3 true WO2004035746A3 (en) 2005-04-28

Family

ID=32108082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/032805 WO2004035746A2 (en) 2002-10-17 2003-10-16 Susceptibility gene for myocardial infarction

Country Status (4)

Country Link
EP (1) EP1562973A4 (en)
AU (1) AU2003290527A1 (en)
CA (1) CA2502359A1 (en)
WO (1) WO2004035746A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
JP2007538003A (en) * 2004-01-30 2007-12-27 デコード ジェネティクス イーエッチエフ． Susceptibility gene for myocardial infarction, stroke and peripheral arterial occlusion disease, treatment method
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
EP1983062A1 (en) * 2007-04-18 2008-10-22 Siemens Healthcare Diagnostics Inc. Single nucleotide polymorphisms associated with susceptibiliy to cardiovascular disease
WO2007014338A2 (en) * 2005-07-26 2007-02-01 Siemens Medical Solutions Diagnostics Single nucleotide polymorphisms associated with susceptibility to cardiovascular disease
EP3205644A1 (en) 2005-12-29 2017-08-16 Celtaxsys Inc. Diamine derivatives as inhibitors of leukotriene a4 hydrolase
KR101571523B1 (en) * 2007-02-21 2015-11-24 디코드 제네틱스 이에이치에프 Genetic susceptibility variants associated with cardiovascular disease
US7883851B2 (en) 2007-05-02 2011-02-08 Board Of Regents, The University Of Texas System Common allele on chromosome 9 associated with coronary heart disease
CZ302379B6 (en) * 2009-12-22 2011-04-20 Ústav informatiky AV CR, v.v.i. Centrum biomedicínské informatiky Method for determining prognosis for patients with primary myocardial infarction and oligonucleotide chip for such determination
US12077823B2 (en) * 2011-08-05 2024-09-03 Genincode Plc Risk assessment for cardiovascular disease
RU2686101C2 (en) 2013-03-12 2019-04-24 Селтакссис, Инк. Methods of inhibiting leucotreen-a4-hydrolases
EP2968265A4 (en) 2013-03-14 2016-12-28 Celtaxsys Inc Inhibitors of leukotriene a4 hydrolase
EP2970309A4 (en) 2013-03-14 2016-11-09 Celtaxsys Inc Inhibitors of leukotriene a4 hydrolase
MX2015011677A (en) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibitors of leukotriene a4 hydrolase.
EP3801559A4 (en) 2018-05-31 2022-03-02 Celltaxis, LLC Method of reducing pulmonary exacerbations in respiratory disease patients

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531279B1 (en) * 1998-04-15 2003-03-11 Genset S.A. Genomic sequence of the 5-lipoxygenase-activating protein (FLAP), polymorphic markers thereof and methods for detection of asthma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531279B1 (en) * 1998-04-15 2003-03-11 Genset S.A. Genomic sequence of the 5-lipoxygenase-activating protein (FLAP), polymorphic markers thereof and methods for detection of asthma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE SNP [online] 10 October 2000 (2000-10-10), XP002983957, Database accession no. RS1323898 *
See also references of EP1562973A4 *

Also Published As

Publication number Publication date
AU2003290527A1 (en) 2004-05-04
CA2502359A1 (en) 2004-04-29
WO2004035746A2 (en) 2004-04-29
EP1562973A2 (en) 2005-08-17
EP1562973A4 (en) 2007-01-03

Similar Documents

Publication Publication Date Title
WO2004035746A3 (en) Susceptibility gene for myocardial infarction
WO2004035741A3 (en) Susceptibility gene for myocardial infarction; methods of treatment
WO1999052942A3 (en) Genomic sequence of the 5-lipoxygenase-activating protein (flap), polymorphic markers thereof and methods for detection of asthma
VanDemark et al. Structural basis of ubiquitylation
WO2006050475A3 (en) Identification of dysregulated genes in patients with neurological diseases
WO2008048119A3 (en) Methods of analysis of polymorphisms and uses thereof
WO2005090393A3 (en) Multimeric protein toxins to target cells having multiple identifying characteristics
WO2004050704A8 (en) Therapeutic and diagnostic agents
Hocharoen et al. Metallotherapeutics: novel strategies in drug design
WO2005108613A3 (en) Human type ii diabetes gene-kv channel-interacting protein (kchip1) located on chromosome 5
WO2008112903A3 (en) Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
WO2003016563A3 (en) Novel molecular target for neurotoxicity
WO2005075022A3 (en) Susceptibility gene for myocardial infraction, stroke, and paod; methods of treatment
WO2006063703A8 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2004037198A3 (en) Antibody-mediated induction of tumor cell death
WO2004041216A3 (en) Ptpn11 (shp-2) mutations and cancer
WO2000022122A3 (en) Genes, proteins and biallelic markers related to central nervous system disease
AU2003239368A1 (en) Targeting proteins to deliver therapeutic or diagnostic reagents
WO2005072186A3 (en) Glyphosate tolerant plants and methods of making and using the same
WO2003029422A3 (en) Noonan syndrome gene
Ashavaid et al. Design of allele specific PCR for rapid detection of CYP3A5 (A6986G) and Mdr-1 (C3435T) polymorphisms
WO2004041193A3 (en) HUMAN TYPE II DIABETES GENE-Kv CHANNEL-INTERACTING PROTEIN (KChIP1) LOCATED ON CHROMOSOME 5
WO2000058510A3 (en) Schizophrenia associated genes, proteins and biallelic markers
WO2003034818A1 (en) Sgrf genetically modified nonhuman animal
Poch et al. Genetic variation of the γ subunit of the epithelial Na+ channel and essential hypertension. Relationship with salt sensitivity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2502359

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003290527

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003783063

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003783063

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP